Non-structural protein 5A (NS5A) inhibitors are a direct-acting antiviral agent used to treat hepatitis C virus (HCV). The NS5A protein has a substantial role in viral replication, packaging, assembly and complex interactions with cellular functions. Therefore NS5A inhibitors treat viral infections by reducing the ability of the virus to replicate. NS5A inhibitors may be used to treat specific HCV genotypes and are often used in conjunction with other antiviral agents.
Name | Updated |
---|---|
Daklinza (Daclatasvir [ dak-lat-as-vir ]) | 13-Jul-2023 |